위더스제약
Financials
Valuation Metrics
위더스제약's Market Cap is ₩902B. At end of 2025 it was ₩1138B. Ranked #1303 of 2,436 in KR market (top 53%), #710 of 1,649 on KOSDAQ (top 43%), #142 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 90.15B KRW | KR#1,303/2,436 Sec#142/234 |
| Revenue | 108.89B KRW | KR#1,348/2,436 Sec#86/234 |
| Net Income | 7.29B KRW | KR#1,000/2,436 Sec#66/234 |
| Total Assets | 142.60B KRW | KR#1,505/2,436 Sec#120/234 |
| Net Assets | 101.98B KRW | KR#1,386/2,436 Sec#113/234 |
| Employees | 218 | KR#1,025/2,436 Sec#85/234 |
| Value | ||
| P/E | 12.36x | KR#844/2,436 Sec#51/234 |
| P/B | 0.88x | KR#1,381/2,436 Sec#86/234 |
| PEG | 0.09x | KR#375/2,436 Sec#21/234 |
| P/S | 0.83x | KR#1,265/2,436 Sec#67/234 |
| EV/EBITDA | 23.96x | KR#1,100/2,436 Sec#66/234 |
| FCF Yield | 6.08% | KR#805/2,436 Sec#39/234 |
| Profitability | ||
| ROE | 7.15% | KR#772/2,436 Sec#53/234 |
| ROA | 5.11% | KR#636/2,436 Sec#49/234 |
| Op. Margin | 3.52% | KR#1,138/2,436 Sec#88/234 |
| Revenue Growth | 9.50% | KR#945/2,436 Sec#83/234 |
| Earnings Growth | 141.19% | KR#333/2,436 Sec#21/234 |
| Financial Health | ||
| Debt Ratio | 139.83% | KR#1,031/2,436 Sec#118/234 |
| Total Debt | 20.75B KRW | KR#1,342/2,436 Sec#110/234 |
| FCF | 5.48B KRW | KR#878/2,436 Sec#59/234 |
| Cash | 19.20B KRW | KR#1,258/2,436 Sec#92/234 |
| Current Ratio | 2.00x | KR#950/2,436 Sec#110/234 |
| Net Debt/EBITDA | 0.40x | KR#738/2,436 Sec#49/234 |
| Dividend | ||
| Div. Yield | 1.53% | KR#1,023/2,436 Sec#57/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -6.44% | KR#861/2,436 Sec#65/234 |
| 1M Return | 7.73% | KR#343/2,436 Sec#24/234 |
| From 52W High | -42.85% | KR#887/2,436 Sec#63/234 |
| 1Y MDD | -49.66% | KR#916/2,436 Sec#75/234 |
| Trading | ||
| Volume | 57,666 shares | KR#1,250/2,436 Sec#123/234 |
| Foreign Own. | 3.69% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 552 KRW | KR#879/2,436 Sec#64/234 |
| BPS | 7,726 KRW | KR#1,099/2,436 Sec#80/234 |
Company Info
Withus Pharmaceutical, headquartered in Seocho-gu, Seoul, was established in 2004 and listed on KOSDAQ in 2020, with its primary business being the production and sale of specialized medicines. The company demonstrates strengths in cardiovascular drugs, operates cephalosporin antibiotic production facilities, and engages in Contract Manufacturing Organization (CMO) services. To expand its market share in aging population and chronic disease markets, Withus Pharmaceutical is strengthening its product lineup and pharmaceutical pipeline. It is also enhancing capabilities by securing manufacturing technologies through strategic collaborations.